PNC-27

PNC-27 is a 32-amino acid chimeric anticancer peptide developed in 2000 by Dr. Matthew Pincus and Dr. Joseph Michl at SUNY Downstate Medical Center using supercomputer modeling. It contains the HDM-2 binding domain of the p53 tumor suppressor protein (residues 12-26) linked to a membrane-penetrating peptide (MRP) derived from the Antennapedia penetratin sequence. PNC-27 selectively kills cancer cells by binding to HDM-2 (MDM2) expressed on cancer cell membranes, forming transmembrane pores that cause rapid necrotic cell death — a process termed 'poptosis.' Normal cells, which lack membrane-associated HDM-2, are unaffected. A 2024 study revealed a secondary mechanism: PNC-27 also enters cells and selectively disrupts mitochondrial membranes while sparing lysosomes. Preclinical studies demonstrate efficacy against pancreatic, breast, melanoma, leukemia, ovarian, cervical, and other cancers. The FDA has issued explicit warnings against PNC-27 use due to contamination risks in marketed products and lack of approval. No verified human clinical trial data exists.

• Multi-Cancer Selectivity
• p53-Independent Mechanism
• Chemotherapy Synergy

Selective cancer cell killing via HDM-2 membrane targeting and mitochondrial disruption. Demonstrated efficacy against multiple cancer types in preclinical studies (pancreatic, breast, melanoma, leukemia, ovarian, cervical). Normal cells unaffected. Synergy with paclitaxel and ketone bodies documented.

PNC-27 contains the p53 HDM-2-binding domain (residues 12-26) linked to a membrane-penetrating peptide. It binds HDM-2 overexpressed on cancer cell membranes, forming oligomeric transmembrane pore complexes that cause rapid necrotic cell death ('poptosis'). A secondary mechanism involves direct mitochondrial membrane disruption. Normal cells lack membrane HDM-2 and are unaffected, regardless of p53 mutation status.

Research protocols from published literature — not dosing recommendations.

• Paclitaxel (Taxol) — Synergistic: Ex vivo studies on patient-derived ovarian cancer cells demonstrated synergy via isobologram analysis. Cancer cells surviving paclitaxel upregulate membrane MDM-2, increasing PNC-27 susceptibility.
• Ketone Bodies (BHB, Acetoacetate) — Synergistic: 2025 peer-reviewed study showed lithium acetoacetate and beta-hydroxybutyrate reduce PNC-27 IC50 by 200-400% via Warburg effect disruption. Ketogenic diet may theoretically enhance efficacy.
• Thymosin Alpha-1 — Unknown: No direct interaction studies. Both have anticancer mechanisms — TA1 via immune modulation, PNC-27 via direct membranolysis. Theoretically complementary but unstudied.
• Chemotherapy (General) — Unknown: Paclitaxel synergy is documented. Other chemotherapies are unstudied but mechanistically compatible given PNC-27's distinct membrane-lytic action.
• Immunotherapy (Checkpoint Inhibitors) — Unknown: No interaction data. PNC-27 induces necrosis which releases tumor antigens, theoretically enhancing immune recognition. Pure speculation — no studies exist.
• Other HDM-2 Inhibitors (Nutlin-3, Idasanutlin) — Unknown: Small molecule HDM-2 inhibitors act intracellularly on wild-type p53 tumors. PNC-27 targets membrane HDM-2 and works in p53-mutant cancers. Potential for additive effects but unstudied.
• BPC-157 / TB-500 — Unknown: No documented interactions with common healing peptides. Different mechanisms and targets. No basis for interaction concern, but no studies confirm safety of combination.

Supplies:

• PNC-27 lyophilized powder
• Bacteriostatic water (BAC water)
• Alcohol swabs
• Insulin syringe (100-unit)

1. 1Clean work area and hands thoroughly
2. 2Calculate required BAC water volume using calculator below
3. 3Draw BAC water into syringe
4. 4Inject slowly down vial side (not directly onto powder)
5. 5Gently swirl until dissolved (never shake)
6. 6Store reconstituted vial in refrigerator at 2-8°C, use within 28 days

NO established human efficacy data — all expectations are based on preclinical research. Preclinical: Cancer cell death occurs within 90 minutes at effective concentrations in vitro. Community protocols suggest 8-12 week cycles, but this is not clinically validated. Injection site reactions are the most commonly reported side effect. FDA has warned against use — consult an oncologist before considering.

NOT FDA approved — FDA has issued explicit warnings against PNC-27 use. FDA found bacterial contamination (Variovorax paradoxus) in marketed PNC-27 products. No verified human clinical trial data published in peer-reviewed journals. No established human safety profile — preclinical data shows selectivity for cancer cells. No published pharmacokinetic data in humans (half-life, bioavailability unknown). Should never replace FDA-approved cancer treatments. Discuss with a qualified oncologist before any consideration of use. Source quality is critical — third-party testing essential. Avoid nebulized/inhalable forms (contamination risk cited by FDA).

NOT FDA approved — FDA has issued explicit warnings against PNC-27 use. FDA found bacterial contamination (Variovorax paradoxus) in marketed PNC-27 products. No verified human clinical trial data published in peer-reviewed journals. No established human safety profile — preclinical data shows selectivity for cancer cells. No published pharmacokinetic data in humans (half-life, bioavailability unknown). Should never replace FDA-approved cancer treatments. Discuss with a qualified oncologist before any consideration of use. Source quality is critical — third-party testing essential. Avoid nebulized/inhalable forms (contamination risk cited by FDA).

PNC-27 should be stored at Lyophilized: -20°C to -80°C | Reconstituted: 2-8°C.